Aytu Biopharma (AYTU) EBT (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of EBT data on file, last reported at -$5.6 million in Q1 2026.

• EBT for Q1 2026 came in at -$5.6 million, down 246.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$33.7 million (down 1165.17% YoY), and the FY2025 annual result was -$13.7 million, down 32.44% from the prior year.
• EBT advanced to -$5.6 million in Q1 2026 per AYTU's latest filing, from -$10.6 million in the prior quarter.
• Over five years, EBT peaked at $3.8 million in Q1 2025 and troughed at -$53.3 million in Q1 2022.
• A 5-year average of -$7.3 million and a median of -$2.5 million in 2024 frame the typical range for EBT.
• On a YoY basis, EBT climbed as much as 316.07% in 2025 and fell as far as 2870.68% in 2025.
• A 5-year view of EBT shows it stood at -$6.7 million in 2022, then surged by 120.9% to $1.4 million in 2023, then tumbled by 72.69% to $382000.0 in 2024, then tumbled by 2870.68% to -$10.6 million in 2025, then jumped by 47.01% to -$5.6 million in 2026.
• Business Quant data shows AYTU's EBT at -$5.6 million in Q1 2026, -$10.6 million in Q4 2025, and $2.0 million in Q3 2025.